Hints and tips:
Related Special Reports
...Novo Nordisk is seeking deals to cement its global lead in weight loss after outlining promising trial results for anti-obesity pills that would extend the Danish drugmaker’s portfolio beyond its injectable...
...US rival Pfizer in December abandoned plans for a weight-loss pill to be taken twice a day after trials showed significant side effects....
...The company’s amycretin oral pill — which has a different formulation to its popular diabetes and weight loss medicines Ozempic and Wegovy — resulted in a 13 per cent weight loss in early stage trials....
...But pills are the holy grail of convenience, making them a key development in the next generation of weight-loss drugs....
...Aardvark Therapeutics, a US biotech group developing a weight loss pill, is planning to raise up to $200mn in an initial public offering as early as this summer, propelled by investor hype over anti-obesity...
...Eli Lilly’s weight-loss drug tirzepatide significantly reduced sleep apnoea problems in a late-stage clinical trial, the pharmaceutical group said on Wednesday, adding to evidence that could encourage more...
...Some users of Medicare, the US government-funded insurance programme for seniors, will be able to access weight-loss drugs if they suffer from certain conditions such as cardiovascular disease, officials...
...“It’s unlikely we have high amounts of spare capacity [in the market].”Novo Nordisk, Eli Lilly, and Pfizer all have weight-loss pills under development, which could solve the fill-finish supply issues....
...Weight loss injections have boosted the fortunes of companies such as Denmark’s Novo Nordisk. A cheaper, oral formulation would be a game-changer, researchers hope....
...Sistani made waves in the weight management industry last year with an acquisition that took the company Jean Nidetch launched in 1963 to run weight-loss support groups into the business of dispensing anti-obesity...
...The booming weight loss drug market — which is expected to be worth $100bn by the end of the decade — is dominated by those two rivals....
...AstraZeneca has signed a licensing agreement with Chinese company Eccogene, which is developing a weight-loss pill, while Swiss pharma group Roche bought obesity drug developer Carmot Therapeutics for $2.7bn...
...While injectables are the only treatments at present on the market, both companies are working on weight loss pills....
...In February’s mid-stage trials, Eli Lilly’s weight loss drug tirzepatide showed promise against MASH....
...Exploring the ESG impact of weight-loss drugs The surging popularity of obesity drugs is having a huge societal impact....
...Clip from Lionsgate Television For further reading: WeightWatchers faces an era when weight loss comes in a syringe Behold the Ozempic effect on business The race to develop the next generation of weight-loss...
...Novo Nordisk’s blockbuster weight loss drugs powered the company to record a 36 per cent increase in sales last year....
...Demand for weight-loss solutions is high in China, where obesity rates among Chinese adults have also more than doubled in less than two decades....
...Novo’s shares hit a new record this month after it revealed early-stage results for an experimental weight-loss pill that appeared to offer better results than Wegovy....
...And weight loss drugs like Ozempic have been in the news a lot. But are we missing their true potential?...
...To do this, the company has launched trials of its weight-loss treatments to show that they can also tackle diseases linked to obesity....
...In December, Pfizer’s shares fell after side-effects forced it to cancel its twice-daily weight loss pill, though it is still pursuing a one-a-day version....
...and dramatic weight-loss results boosting demand....
...The cost of a one-month supply of Ozempic — meant for managing type 2 diabetes — is $969 in the US, while the list price of weight-loss drug Wegovy is $1,349, according to figures cited by Sanders....
International Edition